GenoMed Inc. (GMED): GenoMed Eager to Collaborate With Public...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	59
Posts	9079
Boards Moderated	0
Alias Born	08/20/2000

jmhollen

Re: None

Tuesday, 05/13/2003 5:28:30 PM

Tuesday, May 13, 2003 5:28:30 PM

GenoMed Eager to Collaborate With Public Health Authorities In Clinical Trial Against SARS

ST. LOUIS, May 13 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today that it has initiated discussions with the National Institutes of Health and the Centers for Disease Control (CDC) for assistance in the Company's world-wide clinical trial against SARS.

Steve Mitchell's article for UPI, released last night at 6 p.m., and available at http://www.upi.com/view.cfm?StoryID=20030512-053537-9925r , contained encouraging comments by Dr. Catherine Laughlin of the National Institute of Allergy and Infectious Disease (NIAID), as well as cautiously optimistic comments from Llelwyn Grant, spokesman for the CDC.

Dr. David Moskowitz, Chairman, CEO, and Chief Medical Officer of GenoMed, said, "GenoMed is extremely grateful to Dr. Laughlin and Mr. Grant for their generous comments, and to Steve Mitchell for his excellent reporting. I've just phoned and emailed Dr. Laughlin and Mr. Grant in an attempt to coordinate our activities as quickly as possible. This is one of those medical situations where every minute counts for patients with SARS or at high risk of getting it."

Dr. Moskowitz continued, "At GenoMed we believe that SARS has already shown itself to behave more like asthma than a bacterial pneumonia. Asthma consists of an exaggerated immune response oftentimes to a viral infection that's inconsequential for most people. Like SARS, asthma can kill if the immune response is excessive. The treatment for asthma is to suppress the immune response with inhaled or oral or occasionally intravenous steroids. In treating asthma, nobody even bothers trying to kill the virus which triggers the asthmatic attack. Most of the time we don't know which virus it is."

Dr. Moskowitz ended by saying, "Here we already know a lot about the SARS virus, which is an enormous tribute to the large number of courageous health workers and brilliant scientists who have been working non-stop on this epidemic already. Our approach to treating SARS will be similar to the conventional approach to asthma, except for one additional step: we'll try to prevent serious symptoms in the first place by using an angiotensin II receptor blocker (ARB). From the public health point of view, an ARB is much less worrisome to use than steroids. We'll reserve inhalated steroids for more serious symptoms, in patients who break through our first barrier against the disease, the ARB. We look forward to perhaps collaborating with the NIH and the CDC in this treatment approach."

GenoMed is now accepting volunteers in its world-wide clinical trial against SARS. Click here to learn more about our clinical trial:

http://216.234.225.2/sendFeedBack.asp?B=571&RL=3260&S=5036

Volunteers will receive background information and an informed consent document. They will be instructed to contact their local physician, whose cooperation is required for participation in the study. Depending on their blood pressure, volunteers will be prescribed either a hydrophobic ACE inhibitor or an angiotensin II receptor blocker (ARB, also called "sartan") by their physician, and their clinical course will be observed by their physician. If this treatment works as expected, mortality will be reduced among volunteers relative to non-participants. Angiotensin II blockade for SARS is covered by a provisional patent application already submitted by GenoMed. As is customary with all of GenoMed's clinical trials, volunteers who pioneer GenoMed's treatments will receive free use of that treatment for the life of GenoMed's patent.

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including HIV infection, AIDS, and autoimmune diseases. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed's research results are more fully described on its website, www.genomedics.com

For questions, please contact David W. Moskowitz, MD, MA(Oxon.), FACP at 314-977-0110, FAX 314-977-0042, email: dwmoskowitz@genomedics.com or visit us at www.genomedics.com.

SOURCE GenoMed, Inc.

CONTACT: David W. Moskowitz, MD, MA(Oxon.), FACP, GenoMed, Inc.,
314-977-0110, or fax, 314-977-0042, or email,
dwmoskowitz@genomedics.com/

Web site: http://www.genomedics.com

.......According to the Great Pumpkin, ".....You're in .....iHub....., Charlie Brown....."!!!